Hunger suppression has become one of the most researched areas in metabolic health, and peptides are emerging as leading tools in weight loss. But can peptides suppress hunger?
Peptides are naturally occurring chains of amino acids that act as signalling molecules in your body. They communicate with various receptors to influence everything from metabolism to appetite regulation.
Due to the extent to which particular peptides have been researched, some are now approved for human consumption when prescribed by a medical professional for weight-loss purposes. However, others are not approved for human consumption and are still in the research stages.
Understanding How Peptides Can Suppress Hunger
Most hunger-suppressing peptides work by targeting receptors in the hypothalamus, which is your brain’s appetite control centre. They work by mimicking the natural satiety hormones, reducing hunger signals, slowing gastric emptying and enhancing feelings of fullness.
Each peptide operates through slightly different mechanisms, making some more suitable for specific research applications than others.
We’ve compiled a list of some of the most studied hunger-suppressing peptides.
Retatrutide
Retatrutide represents a significant advancement in appetite-regulating peptides. This compound is a triple agonist, targeting GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors simultaneously.
Published research demonstrates retatrutide’s remarkable effects on hunger suppression. In a phase 2 clinical trial examining adults with type 2 diabetes, participants receiving retatrutide at doses of 4 mg or higher reported significantly greater reductions in overall appetite, hunger, and prospective food consumption compared to the placebo.
The study published promising results:
- Clinical participants on retatrutide 8 mg and 12 mg experienced greater improvements in perceived hunger and disinhibition (tendency to overeat) at both 24 and 36 weeks.
- Dietary restraint increased significantly in participants receiving the 12 mg dose.
- Weight reduction correlated strongly with decreased perceived hunger and reduced disinhibition.
Additional research showed that 31 of 36 retatrutide-treated participants reported changes in eating behaviours within the first 8 weeks of treatment. Participants described eating less frequently, consuming smaller portions, feeling hungry less often, and experiencing greater control over their eating habits.
Clinical trials demonstrated that participants taking the highest dose of 12 mg lost an average of 36.6 pounds over 40 weeks, with A1C levels (a measure of blood sugar control) decreasing by 1.7 to 2%.
The triple-receptor mechanism makes retatrutide particularly effective for appetite control, as it addresses hunger through multiple pathways simultaneously.
Retatrutide is not approved for human consumption.
Semaglutide
Semaglutide has established itself as one of the most well-researched appetite-suppressing peptides available. This GLP-1 receptor agonist mimics a hormone naturally produced by your intestines after eating, sending powerful satiety signals to your brain.
The mechanism is straightforward yet effective. Semaglutide attaches to GLP-1 receptors and has an effect on hunger by:
- Making the stomach take longer to empty so food stays there longer
- Lowering signals in the hypothalamus that increase appetite
- Cutting down cravings for calorie-heavy foods is sometimes called ‘food noise’
- Boosting the sensation of feeling full after eating
Clinical research has consistently demonstrated semaglutide’s ability to reduce hunger and food intake. Participants in multiple studies reported sustained appetite suppression, making it easier to adhere to reduced-calorie diets.
Semaglutide is approved for human consumption but only for specific products manufactured by Novo Nordisk, which are Wegovy and Ozempic.
Tirzepatide
Tirzepatide is a dual agonist, targeting both GIP and GLP-1 receptors. This unique dual-action approach provides a stronger appetite suppression effect when compared to single-receptor agonists.
The compound works by:
- Activating GLP-1 receptors to reduce appetite and slow gastric emptying
- Stimulating GIP receptors to enhance insulin secretion and improve glucose metabolism
Research indicates that tirzepatide’s dual mechanism produces substantial weight loss and appetite reduction. The combination of GIP and GLP-1 receptor activation creates a synergistic effect that may be more effective than targeting either receptor alone.
Tirzepatide is approved for human consumption when used to treat type 2 diabetes, under the product names Mounjaro or Zepbound.
Liraglutide
Liraglutide is one of the original peptides in this niche and has been available for research purposes longer than many other appetite-suppressing peptides, providing an extensive body of evidence regarding its effects on hunger and satiety.
As a GLP-1 receptor agonist, liraglutide functions similarly to semaglutide but with a shorter duration of action.
Liraglutide works by:
- Activating GLP-1 receptors in the brain’s appetite centres, the hypothalamus.
- Reducing hunger signals throughout the day
- Decreasing the ‘food noise’ around cravings, particularly for sweet and fatty foods
- Enhances satiety, or the feeling of fullness and satisfaction after meals.
Research on liraglutide shows that it interacts with how the brain responds to food cues; in doing so, it potentially reduces the appeal of high-calorie foods. Combining this neurological effect with its appetite-suppressing properties makes liraglutide a powerful tool for weight loss. You can find it being marketed under the brand name Saxenda, as it is approved for human consumption when prescribed and monitored by a medical professional.
GLP-1:
GLP-1 has become one of the most well-known peptides surrounding weight loss in recent years. Glucagon-like peptide-1 (GLP-1) is another naturally occurring peptide that is key to appetite control. GLP-1 is produced in the intestines, and as a response to food intake, it is able to:
- Stimulate insulin secretion when blood glucose is elevated.
- Inhibit glucagon release, preventing excessive glucose production.
- Slow gastric emptying prolongs feelings of fullness
- It directly suppresses appetite through brain receptors.
The discovery of GLP-1’s appetite-suppressing properties led to the development of GLP-1 receptor agonists like semaglutide and liraglutide. These synthetic compounds are designed to be more stable and longer-lasting than natural GLP-1, which is rapidly broken down in the body.
How Can Peptides Suppress Hunger
It is a complex mechanism that enables peptides to suppress hunger. Typically, these peptides target the gut, the brain, and metabolic systems. When you eat, it triggers a response that communicates with the brain’s hypothalamus. Peptide release is part of that response, and the peptides work by binding to specific receptors, which then set of a series of signals that work to reduce feelings of hunger, increase feelings of satisfaction, decrease cravings or the need to seek food, and alter the desire for unhealthy foods.
Synthetic peptides designed for appetite suppression work by enhancing or mimicking these natural processes. They’re not forcing your body into an unnatural state; they’re amplifying signals your body already uses to regulate food intake.
The Future of Appetite-Regulating Peptides
Research into appetite-suppressing peptides continues to advance rapidly, with huge potential in how weight loss and weight-related illnesses could be treated.
The development of not-yet-approved peptides such as retatrutide demonstrates the potential for increasingly sophisticated approaches to appetite regulation and hunger suppression. As research progresses, we can expect to see even more effective peptides entering clinical development; however, every peptide has to undergo extensive research and testing before being approved for human use.
Note: You can buy peptides from our store for UK research.
All products are for research purposes only and are not intended for human consumption outside of approved research protocols.
References
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss – PubMed
Liraglutide (Saxenda) for Weight Loss – PubMed
Semaglutide for the treatment of obesity – PubMed
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial – PubMed
Once-Weekly Semaglutide in Adults with Overweight or Obesity – PubMed
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes – PubMed
New Drug: Tirzepatide (Mounjaro™) – PubMed
GLP-1-based medications: Mechanisms involved in obesity treatment – PubMed
GLP-1 and the Neurobiology of Eating Control: Recent Advances – PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial – PubMed
